These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Danese S; Panés J Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794 [TBL] [Abstract][Full Text] [Related]
5. Anti-integrin therapy for inflammatory bowel disease. Park SC; Jeen YT World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202 [TBL] [Abstract][Full Text] [Related]
6. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. Sands BE Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349 [TBL] [Abstract][Full Text] [Related]
9. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Jovani M; Danese S Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911 [TBL] [Abstract][Full Text] [Related]
10. Next-Generation Therapeutics for IBD. Löwenberg M; D'Haens G Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830 [TBL] [Abstract][Full Text] [Related]
11. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Saruta M; Papadakis KA Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260 [TBL] [Abstract][Full Text] [Related]
12. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Lanzarotto F; Carpani M; Chaudhary R; Ghosh S Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596 [TBL] [Abstract][Full Text] [Related]